StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3010% above fair value
$923.34−22.19 (-2.35%)

Close on Nov 19, 2026Market cap $95.52BP/E 20.4Yield –

Regeneron Pharmaceuticals Total Collaboration Revenue by Quarter

Total Collaboration Revenue (Sanofi, Bayer, Roche & Other) ($M) ($M)

Regeneron Pharmaceuticals Total Collaboration Revenue: $3,001M in Q3 2026, up 52.4% from a year earlier. That is the highest of the 33 quarters on record here.

Latest, Q3 2026
3,001
Period ended Sep 30, 2026
Change on a year earlier
+52.4%
1,968 in Q3 2025
History
33 quarters
Since Q4 2017
Sources
26
Documents cited below

Where the Q3 2026 figure comes from

“Table 4 (FY2026Q3): Total collaboration revenue | $ | 3,000.5 | $ | 1,968.4 | $ | 7,355.2 | $ | 5,360.3”

Source: Form 8-K (exhibit991q32026.htm, filed 2026-10-30) ↗

Reported in Form 10-Q / 10-K Consolidated Statements of Operations & Table 4.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal Collaboration Revenue (Sanofi, Bayer, Roche & Other) ($M) ($M)Year on yearSource
Q3 2026Sep 30, 20263,001+52.4%Form 8-K (exhibit991q32026.htm, filed 2026-10-30) ↗
Q2 2026Jun 30, 20262,455+31.9%Form 8-K (exhibit991q22026.htm, filed 2026-07-30) ↗
Q1 2026Mar 31, 20261,900+24.1%Form 8-K (exhibit991q12026.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 20251,971+22.7%Form 8-K (exhibit991q42025.htm, filed 2026-01-30) ↗
Q3 2025Sep 30, 20251,968+18.6%Form 8-K (exhibit991q32026.htm, filed 2026-10-30) ↗
Q2 2025Jun 30, 20251,861+22.1%Form 8-K (exhibit991q22026.htm, filed 2026-07-30) ↗
Q1 2025Mar 31, 20251,531+20.9%Form 8-K (exhibit991q12026.htm, filed 2026-04-29) ↗
Q4 2024Dec 31, 20241,607+17.3%Form 8-K (exhibit991q42025.htm, filed 2026-01-30) ↗
Q3 2024Sep 30, 20241,660+15.4%Form 8-K (exhibit991q32025.htm, filed 2025-10-28) ↗
Q2 2024Jun 30, 20241,524+15.7%Form 8-K (exhibit991q22025.htm, filed 2025-08-01) ↗
Q1 2024Mar 31, 20241,267-8.1%Form 8-K (exhibit991q12025.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 20231,370-13.7%Form 8-K (exhibit991q42024.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 20231,438+36.9%Form 8-K (exhibit991q32024.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 20231,317+26.2%Form 8-K (exhibit991q22024.htm, filed 2024-08-01) ↗
Q1 2023Mar 31, 20231,378+11.8%Form 8-K (exhibit991q12024.htm, filed 2024-05-02) ↗
Q4 2022Dec 31, 20221,587+78.3%Form 8-K (exhibit991q42023.htm, filed 2024-02-02) ↗

Cite this data

StockData. (2026). Regeneron Pharmaceuticals Total Collaboration Revenue ($M), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rev-collab-total

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?